TSVT earnings

Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for

2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. Members of the management team will also be presenting at the following upcoming investor conference: Guggenheim's Inaugural H

Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today re

2seventy bio, Inc. (NASDAQ:TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy

U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter with $181.4 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024.

2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy bi

New strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs Advisory Committee scheduled for March 15, 2024, to review data supporting the supplemental Biologics License Application for Abecma® (idecabtagene vicleucel) for triple-class exposed relapsed or refractory multiple myeloma Abecma generated $56 million U.S. commercial revenue in the fourth quarter of 2023 and $358 million for the full year, shared equally with Bristol Myers Squibb Ended quarter with $221.8 million cash, cash equivalents, and marketable securities; cash runwa

2seventy bio, Inc. (NASDAQ:TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesday, March 13 at 8:00 a.m. ET Live webcasts of the investor conference presentations will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. Replays will be archived on 2s

- Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio's Chief Scientific Officer, Philip Gregory - Chip Baird named incoming Chief Executive Officer; Nick Leschly named incoming Chairman of Board of Directors - - Expected annual cost savings of approximately $150 million in 2024 and $200 million in 2025; cash runway extended beyond 2027 - - Conference call to be held today at 8:00 a.m. ET - 2seventy bio, Inc. (NASDAQ:TSVT), announced today that it is transforming the Company to focus exclusively on the commercializ

2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. A replay of the call will be available on the 2seventy bio website for 30 days following the event. ASH Presentation Details Oral Presentation: Idecabtagene Vicl

Abecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment Abecma generated $69 million U.S. commercial revenue in the third quarter of 2023; $302 million U.S. commercial revenue year-to-date Two solid tumor programs positioned to enter clinical trials in 2024 Ended quarter with $284.3 million cash, cash equivalents, and marketable securities Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for

2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. A replay of the call will be avail

Approximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into at least 2026 to support focus on long-term mission Company to internally advance fewer pipeline programs while expanding collaboration with JW Therapeutics to include new solid tumor and autoimmune programs; Company to gate at-risk investment in bbT369 (NHL) and SC-DARIC33 (AML) programs pending further clinical data readouts CEO Nick Leschly announces plans to step down as CEO and transition to Chairman of Board of Directors; CEO search process has been initiated; CFO Chip Baird promoted to Chief Operating Officer Conferenc

Abecma (idecabtagene vicleucel) generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million 2seventy bio provides update on PLAT-08 study in AML with partner Seattle Children's Ended quarter with $307 million cash, cash equivalents, and marketable securities; maintaining cash runway into 2026 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the second quarter ended June 30, 2023. "We launched 2seventy in late 2021 with the stated mission of delivering more time for people living with cancer

2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. A replay of the call will be availa

Abecma (idecabtagene vicleucel) generated $118 million U.S. commercial revenue in 1Q 2023, supporting upper end of U.S. revenue guidance of $470-570 million U.S. FDA accepted supplemental Biologics License Application (sBLA) based on results from the pivotal phase 3 KarMMa-3 study of Abecma; PDUFA date December 16, 2023 Collaboration with Novo Nordisk delivers proof of concept data for in-vivo gene editing hemophilia A program; triggers $15 million milestone payment from Novo Nordisk Ended quarter with $341.4 million cash, cash equivalents, and marketable securities; maintaining cash runway into 2026 Company to host virtual Research and Development Deep Dive session on May 19, 2023

2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at https://ir.2seventybio.com/. Participants who wish to ask a question may register here at https://register.vevent.com/register/BI458c3098c2a64310b49e967327a906e7 to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes

Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 10% When Adjusted for Foreign Exchange Further Advances Portfolio Renewal Strategy, Achieving Important Milestones Across Therapeutic Areas Adjusts GAAP 2023 EPS Guidance; Affirms Non-GAAP Financial Guidance for 2023 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023, which reflect robust in-line and new product po

Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3 million milestone payment from 2seventy bioStrengthened leadership with key hires in Corporate Development & Strategy, Investor Relations & Corporate Communications and Clinical Research & DevelopmentCash runway maintained through 4Q 2024Company to host a conference call today, March 29, 2023, at 3 pm CET/ 9 am ET Martinsried/Munich, March 29, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T ce

Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Bolsters New Product Portfolio with FDA Approval for SotyktuTM, a First-in-Class TYK2 inhibitor for Adults with Moderate-to-Severe Plaque Psoriasis Continues to Progress Product Pipeline with Significant Regulatory and Clinical Milestones Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncolog

ABECMA generated $72M U.S. commercial revenue in 2Q; continues to track toward upper end of $250-$300M revenue guidance for 2022 Results from prespecified interim analysis of KarMMa-3 trial shows ABECMA (idecabtagene vicleucel) significantly improves progression-free survival versus standard regimens in relapsed and refractory multiple myeloma Ended quarter with $399M cash, cash equivalents, and marketable securities; revising 2022 net cash spend to $245-265M; maintaining cash runway into 2025 Conference call at 8:00 a.m. ET 2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the second quarter ende